Brief: Gilead Sciences To Buy Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases

Lakefront Biotherapeutics NV

23/03/2026 22:18

March 23 (Reuters) - Gilead Sciences Inc GILD.O:

GILEAD SCIENCES TO ACQUIRE OURO MEDICINES TO ADVANCE FIRST IN CLASS T CELL ENGAGER PROGRAM FOR AUTOIMMUNE DISEASES

GILEAD: WILL ACQUIRE ALL OF OUTSTANDING EQUITY OF OURO MEDICINES FOR A TOTAL OF $1,675 MILLION IN UPFRONT CASH CONSIDERATION

GILEAD - CURRENTLY IN ADVANCED TALKS WITH GALAPAGOS WITH RESPECT TO POTENTIAL RESEARCH AND DEVELOPMENT COLLABORATION ON ACQUIRED OURO MEDICINES ASSETS

GILEAD: GALAPAGOS TO PAY 50% OF UPFRONT CONSIDERATION AND 50% OF ANY CONTINGENT MILESTONE PAYMENTS PAYABLE TO OURO MEDICINES' SHAREHOLDERS

GILEAD: WOULD RETAIN SOLE WORLDWIDE COMMERCIALIZATION RIGHTS OTHER THAN IN GREATER CHINA, CO WOULD PAY GALAPAGOS ROYALTIES OF 20%-23% OF NET SALES

GILEAD:  OURO MEDICINES TO GET UP TO $500 MILLION IN CONTINGENT MILESTONE PAYMENTS

Source text: ID:nBw11kPqva

Further company coverage: GILD.O

 ((Reuters.Briefs@thomsonreuters.com))